StockData

Acadia Pharmaceuticals vs ANI Pharmaceuticals

ACAD and ANIP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACAD and ANIP compare

Acadia Pharmaceuticals is the larger company, worth 2.0 times as much as ANI Pharmaceuticals ($3.2B against $1.6B).

On earnings, Acadia Pharmaceuticals is cheaper: it trades at 8.4× trailing earnings, against 15.1× for ANI Pharmaceuticals.

ANI Pharmaceuticals grew revenue faster over the last twelve months (30.9% versus 11.8% for Acadia Pharmaceuticals).

Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with 11.1% at ANI Pharmaceuticals.

Acadia Pharmaceuticals scores higher on the StockData Score (16 against 14 for ANI Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACADANIP
Size and price
Market cap$3.2B$1.6B
Share price$18.67$70.89
Change, 1 year−21.0%−16.2%
Change, 5 years−0.64%73.9%
Beta (5Y)0.510.63
Employees798970
StockData Score
Total score16 (better)14
Valuation score45 (better)
Growth score22
Performance score44
Health score6 (better)3
Dividend score00
Valuation
P/E8.4× (better)15.1×
P/S2.8×1.7× (better)
P/B2.5× (better)2.7×
EV/EBITDA26.2×6.6× (better)
P/FCF22.1×9.4× (better)
FCF yield4.5%10.6% (better)
Fair value$25.35$134.15
Margin of safety26.4%47.2% (better)
Growth
Revenue growth (TTM)11.8%30.9% (better)
Revenue growth, 5Y average19.4%33.5% (better)
Net income growth (TTM)71.3%–
EPS growth (TTM)66.2%–
Profitability
Gross margin91.1% (better)60.4%
Operating margin7.6%15.4% (better)
Net margin33.4% (better)11.1%
FCF margin12.8%17.7% (better)
Return on equity35.7% (better)21.0%
Return on invested capital42.1% (better)21.3%
Financial health
Debt / equity0.000.50 (better)
Net debt / EBITDA–−0.25
Interest coverage–4.8×
Current ratio3.39 (better)2.91
Altman Z-score4.41 (better)2.54
Piotroski F-score67 (better)
Dividends and buybacks
Payout ratio–0.32%
Buyback yield−1.5%1.4% (better)
Shareholder yield−1.5%1.4% (better)
Ownership
Held by institutions97.9%100%
Held by insiders27.8%12.3%
Insider net buying, 12 months−$2.5M (better)−$13.6M
Short interest, % of float6.7%17.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.